+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Primary Progressive Multiple Sclerosis Market: By Diagnosis, Treatment Centre & By Region - Forecast 2016-2021

  • ID: 3974097
  • Report
  • 147 pages
  • IndustryARC
1 of 2
Primary progressive multiple sclerosis (PPMS) is type of multiple sclerosis (MS) disease which affects nervous system by causing inflammation. Multiple sclerosis is also referred as disseminated sclerosis. Such diseases causes damages to the nervous system and affects its communication and causes other problems, which includes various other mental, physical and psychiatric problems. Under primary progressive multiple sclerosis (PPMS)] neurological functions are steadily deteriorated with minimal distinct relapses (exacerbations and attacks) or the fixed period remissions. The progression rates of PPMS may vary from person to person and over the timeframes, which may show the signs of transitory improvements, however, the progression of disease remains persistent. Currently increasing population with MS is driving the global PPMS market and is expected to continue during the period of study.

This report identifies the global primary progressive multiple sclerosis market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global primary progressive multiple sclerosis market.

Geographically North America dominated global primary progressive multiple sclerosis market due to higher awareness about the diseases amongst citizens coupled with advanced and well developed healthcare infrastructure with easy accessibility to each of the citizens. North America was followed by Europe and Asia-Pacific as second and third largest markets for primary progressive multiple sclerosis. Asia Pacific is projected to have fastest growth, owing to rapidly growing healthcare infrastructure in the major developing economies such as India and China along with rising aware amongst practitioners and people in the region.

This report segments global primary progressive multiple sclerosis market on the basis of diagnosis type, treatment centre and regional market as follows:

This report on primary progressive multiple sclerosis market is segment on the basis of diagnosis type covering three major diagnosis types as follows: Magnetic Resonance Imaging (MRI) Scans, Simple electrical stimulation tests, Lumbar puncture
On the basis of treatment centre, this report on primary progressive multiple sclerosis market is segmented into three major segments as follows:, Hospital testing (Commercial/private hospitals, Public health hospitals, Symptomatic diagnostic testing with medications), Clinics, Home Treatment (Managing symptoms, Rehabilitation, Healthy living)
This report on primary progressive multiple sclerosis has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the primary progressive multiple sclerosis market. Some of the major companies’ profiles in detail are as follows:

F. Hoffmann-La Roche Ltd.

Innate Immunotherapeutics Limited
Biogen Idec
Teva Pharmaceuticals
Bayer Healthcare
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 2
1. Primary Progressive Multiple Sclerosis Market – Market Overview

2. Executive Summary

3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis

4. Primary Progressive Multiple Sclerosis Market– Market Forces
4.1. Drivers
4.1.1. Rising global population with multiple sclerosis
4.2. Restraints
4.2.1. Unawareness about disease in developing nations
4.3. Opportunities
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Primary Progressive Multiple Sclerosis Market – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life cycle Analysis
5.5. Suppliers & Distributors

6. Primary Progressive Multiple Sclerosis Market, By Diagnosis Type
6.1. Magnetic Resonance Imaging (MRI) Scans
6.2. Simple electrical stimulation tests
6.3. Lumbar puncture

7. Primary Progressive Multiple Sclerosis Market, By Treatment Centre
7.1. Hospital testing
7.1.1. Commercial/private hospitals
7.1.2. Public health hospitals
7.1.3. Symptomatic diagnostic testing with medications
7.2. Clinics
7.3. Home Treatment
7.3.1. Managing symptoms
7.3.2. Rehabilitation
7.3.3. Healthy living

8. Primary Progressive Multiple Sclerosis Market, By Geography
8.1. Europe
8.1.1. Germany
8.1.2. France
8.1.3. Italy
8.1.4. Spain
8.1.5. Russia
8.1.6. U.K.
8.1.7. Rest of Europe
8.2. Asia Pacific
8.2.1. China
8.2.2. India
8.2.3. Japan
8.2.4. South Korea
8.2.5. Rest of Asia-Pacific
8.3. North America
8.3.1. U.S.
8.3.2. Canada
8.3.3. Mexico
8.4. Rest of the World (RoW)
8.4.1. Brazil
8.4.2. Rest of RoW

9. Primary Progressive Multiple Sclerosis – Market Entropy
9.1. Expansion
9.2. Technological Developments
9.3. Merger & Acquisitions, and Joint Ventures
9.4. Supply- Contract

10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
10.1. F. Hoffmann-La Roche Ltd.
10.2. Innate Immunotherapeutics Limited
10.3. Biogen Idec
10.4. Teva Pharmaceuticals
10.5. Bayer Healthcare
10.6. Pfizer Inc.
10.7. Sanofi-Aventis
10.8. Merck
10.9. Novartis.
* More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"Financials would be provided on a best efforts basis for private companies"

11. Appendix
11.1. Abbreviations
11.2. Sources
11.3. Research Methodology
11.4. Bibiliography
11.5. Compilation of Expert Insights
11.6. Disclaimer
Note: Product cover images may vary from those shown
3 of 2